JP2007504237A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504237A5
JP2007504237A5 JP2006525420A JP2006525420A JP2007504237A5 JP 2007504237 A5 JP2007504237 A5 JP 2007504237A5 JP 2006525420 A JP2006525420 A JP 2006525420A JP 2006525420 A JP2006525420 A JP 2006525420A JP 2007504237 A5 JP2007504237 A5 JP 2007504237A5
Authority
JP
Japan
Prior art keywords
antigen
complex
scaffold
cell
scaffold complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525420A
Other languages
English (en)
Japanese (ja)
Other versions
JP5097400B2 (ja
JP2007504237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/028492 external-priority patent/WO2005037190A2/en
Publication of JP2007504237A publication Critical patent/JP2007504237A/ja
Publication of JP2007504237A5 publication Critical patent/JP2007504237A5/ja
Application granted granted Critical
Publication of JP5097400B2 publication Critical patent/JP5097400B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006525420A 2003-09-03 2004-09-01 複合ワクチン Expired - Fee Related JP5097400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50021603P 2003-09-03 2003-09-03
US60/500,216 2003-09-03
PCT/US2004/028492 WO2005037190A2 (en) 2003-09-03 2004-09-01 Multiplex vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011109512A Division JP2011231111A (ja) 2003-09-03 2011-05-16 複合ワクチン

Publications (3)

Publication Number Publication Date
JP2007504237A JP2007504237A (ja) 2007-03-01
JP2007504237A5 true JP2007504237A5 (enExample) 2007-09-27
JP5097400B2 JP5097400B2 (ja) 2012-12-12

Family

ID=34465066

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006525420A Expired - Fee Related JP5097400B2 (ja) 2003-09-03 2004-09-01 複合ワクチン
JP2011109512A Withdrawn JP2011231111A (ja) 2003-09-03 2011-05-16 複合ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011109512A Withdrawn JP2011231111A (ja) 2003-09-03 2011-05-16 複合ワクチン

Country Status (7)

Country Link
US (1) US20070014807A1 (enExample)
EP (2) EP2481422A3 (enExample)
JP (2) JP5097400B2 (enExample)
AU (1) AU2004281634B2 (enExample)
CA (1) CA2537900A1 (enExample)
IL (1) IL174020A0 (enExample)
WO (1) WO2005037190A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842480B2 (en) 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
AU2006229549B2 (en) * 2005-03-31 2011-04-07 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of Mycobacterium infections and tuberculosis disease
WO2007070660A2 (en) * 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
EP2170931A4 (en) * 2007-06-15 2010-06-30 Immurx Inc USE OF TLR AGONISTS AND / OR TYPE 1 INTERFERONS TO MITIGATE THE TOXICITY OF THERAPEUTIC REGIMES OF TNF-R AGONISTS
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
JP2011500569A (ja) * 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2276495B1 (en) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US9297005B2 (en) 2009-04-13 2016-03-29 President And Fellows Of Harvard College Harnessing cell dynamics to engineer materials
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
EP2477655A4 (en) 2009-09-14 2014-02-12 Baylor Res Inst VACCINES TREATED ON LANGERHANS CELLS
US9610328B2 (en) 2010-03-05 2017-04-04 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
CA2798739A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
WO2011152995A1 (en) * 2010-06-04 2011-12-08 Bolt Biopharma, Inc. Synthetic proteins containing t cell epitopes for use as immunogenic compositions
WO2011163669A2 (en) 2010-06-25 2011-12-29 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
HUE052853T2 (hu) 2010-10-08 2021-05-28 Scherer Technologies Llc R P Orális vakcina gyorsan oldódó dózisforma, keményítõ alkalmazásával
US10016371B2 (en) * 2010-10-22 2018-07-10 University Of Florida Research Foundation Antigen-specific, tolerance-inducing microparticles and uses thereof
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
US10647959B2 (en) 2011-04-27 2020-05-12 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
CN103648489A (zh) * 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
US20130034482A1 (en) * 2011-08-05 2013-02-07 Chevron U.S.A Inc. Reduction of oxides of nitrogen in a gas stream using molecular sieve ssz-23
WO2013039989A1 (en) * 2011-09-12 2013-03-21 Pds Biotechnology Corporation Particluate vaccine formulations
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
DK2838515T3 (da) 2012-04-16 2020-02-24 Harvard College Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
CN113144188A (zh) 2012-09-21 2021-07-23 Pds生物科技公司 改进的疫苗组合物和使用方法
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US10441649B2 (en) * 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
JP6121597B1 (ja) * 2016-06-09 2017-04-26 株式会社スリービー 免疫応答活性化サイトカイン産生促進剤およびＴｈ１７細胞分化促進剤
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
AU2018243910B2 (en) 2017-03-28 2025-04-10 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
SG11202101973YA (en) 2018-09-12 2021-03-30 Childrens Medical Ct Corp Pneumococcal fusion protein vaccines
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245778T3 (es) * 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
GB2282813A (en) * 1993-10-15 1995-04-19 Merck & Co Inc Annular antigen scaffolds comprising thioether linkages
AU6832398A (en) * 1997-03-27 1998-10-22 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
CZ298364B6 (cs) * 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
JP2002504342A (ja) * 1998-02-19 2002-02-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用
CA2323632A1 (en) * 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
SK4272001A3 (en) * 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
CA2425648A1 (en) * 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
CA2440197A1 (en) * 2001-02-19 2002-08-29 Pharmexa A/S Synthetic vaccines comprising polyhydroxypolymer carriers
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
JP2004527263A (ja) * 2001-05-30 2004-09-09 フォンダツィオーネ テレソン 免疫抑制活性を有するエクスビボ単離ｃｄ２５＋ｃｄ４＋ｔ細胞とその使用
JP3642301B2 (ja) * 2001-07-31 2005-04-27 日本電気株式会社 パケット監視方式
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法

Similar Documents

Publication Publication Date Title
JP2007504237A5 (enExample)
Storni et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles
CN103402539B (zh) 一种用于产生对抗病原体的持久免疫和保护的合成免疫原
Fifis et al. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice
JP2007501602A5 (enExample)
TW514530B (en) Tumor vaccines and methods for their production
JP2011519847A5 (enExample)
US20230172869A1 (en) A nano-enabled vaccination approach for coronavirus disease (covid-19) and other viral diseases
WO2012122396A1 (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
KR20080013850A (ko) 면역원성 분자
JP4713638B2 (ja) ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン
RU2009110969A (ru) Композиции, вызывающие специфический ответ цитотоксических т-лимфоцитов, включающие лимфоаблативное соединение и молекулу, содержащую антигенные последовательности и нацеленную на специализированные антигенпрезентирующие клетки
CN103768595B (zh) 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗
JP2010508857A5 (enExample)
Peacey et al. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response
JP2021519762A (ja) ワクチン組成物
TWI754817B (zh) 以人工混雜ｔ輔助細胞抗原決定位以有限度的ｔ細胞發炎反應促進目標抗體的生產
EP2519263B1 (en) Lipopeptide- and lipoprotein-conjugates and its use
CN107286244B (zh) 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN113906046A (zh) 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽
EP1029549B1 (en) Formulation of nucleic acids and acemannan
KR20180080178A (ko) 세균성 백신 및 바이러스성 백신 방법
Lei et al. CD40L-adjuvanted DNA vaccine carrying EBV-LMP2 antigen enhances anti-tumor effect in NPC transplantation tumor animal
EP3517542B1 (en) Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide
CA2560891A1 (fr) Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations